Skip to Content

Join the 'Kovaltry' group to help and get support from people like you.

Kovaltry News

FDA Approves Bayer's Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A

Posted 18 Mar 2016 by

WHIPPANY, N.J., March 17, 2016 /PRNewswire/ – The U.S. Food and Drug Administration has approved Bayer's Kovaltry Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based on results from the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials, which supported the approval of Kovaltry for routine prophylaxis to reduce the frequency of bleeding episodes. Kovaltry can be used two or three times per week in adolescents and adults, and two or three times per week or every other day in children. "In the LEOPOLD trials, Kovaltry reduced bleeding episodes in patients with hemophilia A when infused twice to three times per week with routine prophylaxis," said Sanjay P. Ahuja, MD, LEOPOLD investigator and Director, Hemostasis & Thrombosis Center ... Read more

Related support groups: Antihemophilic Factor, Hemophilia A, Kovaltry

Ask a Question

Further Information

Related Condition Support Groups

Hemophilia A

Kovaltry Patient Information at